Background: Oesophageal hypervigilance and anxiety can drive symptom experi-
| INTRODUCTION
Chronic conditions affecting the oesophagus, including gastro-oesophageal reflux disease (GERD), eosinophilic oesophagitis, achalasia and functional oesophageal disorders, represent a substantial percentage of the current work load in gastroenterology practices. 1, 2 In ambulatory settings, there are over 7 million diagnoses per year for GERD and over 1.1 million diagnoses for dysphagia. 2 In comparison, the overall number of diagnoses for ulcerative colitis and hepatitis C were approximately 720 000 and 670 000 per year respectively.
Oesophageal disorders are associated with substantial morbidity and mortality. [1] [2] [3] Additionally, these conditions are associated with severe symptoms that substantially reduce quality of life and generate significant healthcare expenditures. [4] [5] [6] [7] [8] [9] The management of symptomatic oesophageal disorders is complex due to the complicated interaction of the brain and gut. 10, 11 While symptoms in the oesophagus can be directly related to underlying inflammatory (eg oesophagitis) or motility (eg achalasia)
issues, there is a significant disconnect between symptom severity and the underlying disease process, 12, 13 indicating other processes likely influence symptom triggering and experience. [10] [11] [12] [13] [14] [15] Furthermore, oftentimes patients continue to experience symptoms despite effective first-line treatments, leaving these patients with inadequate treatment outcomes. 13, 16 The reason for this disconnect lies in the complexity of how oesophageal events are perceived and acted upon. Perception of oesophageal stimuli is a complex process dependent on both peripheral and centrally mediated neurologic processes. 17 Most of the current research focused on evaluating the correlation between physiologic abnormalities of the oesophagus and symptoms is hampered by the fact that these psychological stressors and cognitive factors have not been considered as important confounders and modulators of the symptom experience. Specifically, oesophageal hypersensitivity involves the perception of stimuli not normally perceived (ie allodynia) and the experience of pain and discomfort at higher intensity than would typically be perceived (ie hyperalgesia). 18 Oesophageal hypersensitivity is mediated by a variety of factors, including peripheral sensory inputs (ie peripheral sensitization to noxious stimuli) and factors impacting central processing, such as enhanced synaptic transmission leading to central sensitization. 19, 20 Both increased emotional arousal or mood state 21 
| Symptom assessment
Symptoms were assessed by patient completion of written questionnaires at the time of HRM.
| Gastro-oesophageal reflux questionnaire (GERDQ)
The GerdQ is a 6-item self-report measure used to support healthcare professionals in the diagnosis of GERD, assess the relative impact of GERD on patient's lives and measure response to treatment over time. 30 Participants are asked questions regarding the frequency of their GERD symptoms over the past 7 days. Each question has 5 response options ranging in value from 0 to 3. Higher scores denote more symptoms.
| Brief oesophageal dysphagia questionnaire (BEDQ)
The BEDQ is a 10-item, recently validated self-report measure of oesophageal dysphagia that also assesses for food impactions. 31 The frequency and difficulty with swallowing solid foods, soft foods and liquids are rated on a 5-point Likert scale for 8 items over the past 30 days. An additional 2 items measure how many instances of food impaction lasting more than 30 minutes or requiring an emergency department visit occurred in the past year.
| Quality of life assessment
Health-related quality of life was assessed by patient completion of the following at time of HRM:
| NIH PROMIS Global Health Scale
The PROMIS Global Health short form is a 10-item instrument representing degradations in multiple domains of health-related quality of life: overall physical health, mental health, social health, pain, fatigue and overall perceived quality of life. 32, 33 The scale yields an overall total score as well as a global physical health (GPH) score and a global mental health (GMH) score. T-scores are available for the GPH and GMH scales with a normative average of 50. Higher scores denote better HRQOL.
| Northwestern Oesophageal Quality of Life Scale (NEQOL)
The NEQOL is a 14-item self-report measure assessing disease-specific health-related quality of life including social function, emotional distress, eating impact, sleep and financial burden in patients with oesophageal symptoms over the past 2 weeks. 6 Each question is rated on a 5-point Likert scale ranging from 4 = "Not True at all" to 0 = "Very True." Higher scores denote greater quality of life.
| Statistical analysis
Data were exported into SPSS v23 for Macintosh (Chicago, IL). Preliminary evaluation for normal distribution of the EHAS was performed using standardized cut-off scores <2.0 to >À2.0 for skewness and was performed via independent samples t tests to compare patients measuring "Normal to High" to those measuring "Normal to Low" on the EHAS as determined via median split of the total EHAS score.
Statistical significance is set at P < 0.05 for all analyses with the exception of t tests which used P < 0.01 (Bonferroni correction) to control for Type 1 error.
| RESULTS
The EHAS was completed by 982 individual patients (mean AE SD age 53 AE 15 years; 598, 61%, female) during the study period.
Younger patients reported slightly higher EHAS scores (r = À.14, and r = .758 (Q9 and Q10) with all P < 0.001, indicating each question uniquely contributes to the EHAS score and is sufficiently associated with other items without achieving multicollinearity. As such, no items were removed from the original 15-item scale. PCFA produces two subscale scores: Scale 1 (9 items, eigenvalue = 7.72), measuring symptom-specific anxiety that accounts for 51.5% of the variance in EHAS score and Scale 2, measuring symptom-specific hypervigilance (6 items, eigenvalue = 1.28), accounting for 8.6% of variance in score. Both subscale scores are normally distributed. The rotated component matrix is presented in Table 2 . Additional PCFA conducted for the symptom-specific anxiety and the symptom-specific hypervigilance subscales did not yield any additional delineation of EHAS items for scoring purposes.
Mean scores for each scale are presented in Table 3 and correlations between HRQOL, symptom severity and the EHAS in The EHAS is designed to assess hypervigilance and anxiety across oesophageal diagnoses. However, we found certain subpopulations may be more likely to score higher in these domains including younger patients and patients presenting with chest pain as their primary complaint. Conversely, we observed that patients with major disorders of peristalsis, including distal oesophageal spasm and absent contractility, were more likely to score lower on the EHAS.
Future studies should aim to evaluate differences in oesophageal hypervigilance and anxiety across diagnoses to identify patient populations at greater risk of their symptoms being exacerbated by these processes and for referral to appropriate treatment.
Oesophageal hypersensitivity is likely moderated by symptomspecific anxiety and hypervigilance, with anxiety potentially having a greater impact on patient symptom experiences. Symptom anxiety is well studied in other groups, such as irritable bowel syndrome 24, [34] [35] [36] [37] [38] and functional dyspepsia, [39] [40] [41] and is associated with poorer patient outcomes. However, prior research has fallen short in its understanding of the psychological processes in oesophageal disease course, often focusing on depression, anxiety and somatization [42] [43] [44] [45] rather than investigating visceral sensitivity, patient perceptions and vigilance and central arousal.
Oesophageal hypervigilance can be considered a specific form of interoceptive sensitivity to oesophageal symptoms that plays a role in the development and maintenance exacerbation of functional oesophageal symptoms. An oesophageal stimulus is perceived peripherally by afferent nerves in the vagus, primarily focused on mechanical sensation and reflex mediated responses and spinal afferent pathways associated with pain and nociception. The processing of these signals in the brain is complex and although neuroimaging provides insight into structural and functional components, there is a paucity of information regarding the cognitive-evaluative and affective-motivational domain of oesophageal symptom perception and severity. 46 Oesophageal hypervigilance uniquely contributes to oesophageal hypersensitivity and significantly increases disease burden and impairment in quality of life. These same processes often increase anxiety and may subsequently drive individuals to engage in behaviours aiming to prevent symptoms from occurring and/or to minimize the consequences of symptoms when they do occur.
In anxiety literature, these behaviours are referred to as safety behaviours and often involve avoidance of various activities and result in significant disruption to one's daily life (eg elimination of certain foods, eating only in certain places or at specific times, excessive water consumption) and overall quality of life. As individuals continue to selectively attend to oesophageal sensations, they may begin to interpret even normal bodily or digestive sensations as symptoms, which can drive increased hypervigilance and the development of new and more drastic safety and avoidance behaviours since their current regimen appears insufficient. Additionally, as is often found in individuals with panic disorder, hypervigilance to symptoms can trigger the sympathetic nervous system response, which may drive symptom experience by aggravating oesophageal hypersensitivity. Unfortunately, hypervigilance and catastrophic thinking are reinforced both when symptoms do and when they do not occur. When they do not occur, individuals may attribute this to the effectiveness of their attentiveness to potential symptoms and to their attempts to avoid perceived triggers. 15 Previous research in GERD finds perceptions of reflux symptoms are associated with psychosocial distress, reduced QOL and sensation of dysphagia among patients who are nonresponsive to proton pump inhibitor (PPI) therapy who also have normal impedance-pH. 12 Among these PPI refractory patients, patient-reported symptom severity is associated with physiologic differences, as opposed to psychosocial factors. These results highlight the delicate interplay between psychosocial factors and abnormal physiology in predicting symptom severity in GERD and should be further evaluated in other oesophageal patient groups using the EHAS. Additionally, the present study does not assess the relationship between the hypervigilance measured via the EHAS and established measures of visceral hypersensitivity which we suspect would be at least modest in size.
Future studies may aim to evaluate this relationship and how it presents across the spectrum of oesophageal diseases.
While the present study has several strengths, including a large sample of well-defined oesophageal patients, limitations exist that should be considered in its interpretation. We do not know the racial and ethnic composition of the study sample, as such caution should be taken when applying the findings to minority groups. The data were retrospectively collected and may be prone to collection or abstraction error; future prospective studies with the EHAS can serve to correct this and further validate the measure, including in more diverse patient groups.
These findings demonstrate that the EHAS is a brief, easily administered, valid self-measure of oesophageal symptom-specific anxiety and hypervigilant behaviour. Measurement of oesophageal hypervigilance and anxiety is not only an essential component in the diagnosis and treatment of functional oesophageal disorders but also an important factor to account for when assessing symptom severity among other oesophageal disorders. Thus, the EHAS should have significant utility in future research and in measuring symptom-based treatment outcomes across oesophageal conditions.
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